News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
724,382 Results
Type
Article (41400)
Company Profile (270)
Press Release (682702)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (205194)
Career Advice (2039)
Deals (35600)
Drug Delivery (111)
Drug Development (81532)
Employer Resources (173)
FDA (16442)
Job Trends (14989)
News (347243)
Policy (32847)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2586)
Accelerated approval (34)
Adcomms (25)
Allergies (143)
Alliances (49693)
ALS (170)
Alzheimer's disease (1681)
Antibody-drug conjugate (ADC) (314)
Approvals (16712)
Artificial intelligence (520)
Autoimmune disease (160)
Automation (42)
Bankruptcy (361)
Best Places to Work (11654)
BIOSECURE Act (20)
Biosimilars (193)
Biotechnology (177)
Bladder cancer (159)
Brain cancer (57)
Breast cancer (644)
Cancer (4851)
Cardiovascular disease (406)
Career advice (1721)
Career pathing (37)
CAR-T (283)
CDC (46)
Celiac Disease (2)
Cell therapy (750)
Cervical cancer (36)
Clinical research (69718)
Collaboration (1719)
Company closure (4)
Compensation (1176)
Complete response letters (57)
COVID-19 (2723)
CRISPR (93)
C-suite (865)
Cystic fibrosis (143)
Data (6294)
Decentralized trials (2)
Denatured (25)
Depression (134)
Diabetes (504)
Diagnostics (6722)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (255)
Drug pricing (186)
Drug shortages (28)
Duchenne muscular dystrophy (233)
Earnings (90407)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117716)
Executive appointments (981)
FDA (19587)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1483)
Gene editing (199)
Generative AI (44)
Gene therapy (600)
GLP-1 (967)
Government (4687)
Grass and pollen (6)
Guidances (384)
Healthcare (18962)
HIV (62)
Huntington's disease (45)
IgA nephropathy (84)
Immunology and inflammation (256)
Immuno-oncology (58)
Indications (118)
Infectious disease (2999)
Inflammatory bowel disease (193)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (254)
Interviews (317)
IPO (16670)
IRA (51)
Job creations (3668)
Job search strategy (1438)
JPM (58)
Kidney cancer (16)
Labor market (86)
Layoffs (548)
Leadership (33)
Legal (7981)
Liver cancer (91)
Longevity (15)
Lung cancer (655)
Lymphoma (379)
Machine learning (42)
Management (59)
Manufacturing (808)
MASH (164)
Medical device (13808)
Medtech (13864)
Mergers & acquisitions (20007)
Metabolic disorders (1274)
Multiple sclerosis (164)
NASH (16)
Neurodegenerative disease (320)
Neuropsychiatric disorders (88)
Neuroscience (2923)
Neurotech (1)
NextGen: Class of 2026 (6542)
Non-profit (4546)
Now hiring (68)
Obesity (598)
Opinion (266)
Ovarian cancer (167)
Pain (199)
Pancreatic cancer (231)
Parkinson's disease (282)
Partnered (33)
Patents (507)
Patient recruitment (497)
Peanut (56)
People (59114)
Pharmaceutical (62)
Pharmacy benefit managers (31)
Phase 1 (21723)
Phase 2 (30685)
Phase 3 (22862)
Pipeline (5430)
Policy (286)
Postmarket research (2571)
Preclinical (9229)
Press Release (64)
Prostate cancer (241)
Psychedelics (49)
Radiopharmaceuticals (285)
Rare diseases (847)
Real estate (5981)
Recruiting (70)
Regulatory (24607)
Reports (53)
Research institute (2402)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (16)
RSV (80)
Schizophrenia (148)
Series A (242)
Series B (192)
Service/supplier (11)
Sickle cell disease (97)
Special edition (23)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3630)
State (2)
Stomach cancer (18)
Supply chain (105)
Tariffs (84)
The Weekly (54)
Vaccines (1017)
Venture capital (89)
Weight loss (381)
Women's health (93)
Worklife (18)
Date
Today (149)
Last 7 days (564)
Last 30 days (2379)
Last 365 days (29950)
2026 (3943)
2025 (30211)
2024 (35273)
2023 (40129)
2022 (51250)
2021 (55763)
2020 (54184)
2019 (46687)
2018 (35148)
2017 (32189)
2016 (31594)
2015 (37646)
2014 (31399)
2013 (26499)
2012 (28691)
2011 (29421)
2010 (27495)
Location
Africa (744)
Alabama (84)
Alaska (7)
Arizona (310)
Arkansas (13)
Asia (39371)
Australia (6432)
California (11393)
Canada (3316)
China (1103)
Colorado (480)
Connecticut (484)
Delaware (340)
Europe (85079)
Florida (1708)
Georgia (360)
Hawaii (3)
Idaho (61)
Illinois (869)
India (69)
Indiana (526)
Iowa (22)
Japan (436)
Kansas (127)
Kentucky (40)
Louisiana (26)
Maine (72)
Maryland (1401)
Massachusetts (8150)
Michigan (327)
Minnesota (631)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (79)
New Jersey (3043)
New Mexico (28)
New York (3004)
North Carolina (1470)
North Dakota (8)
Northern California (5572)
Ohio (338)
Oklahoma (21)
Oregon (41)
Pennsylvania (2303)
Puerto Rico (24)
Rhode Island (48)
South America (1131)
South Carolina (67)
South Dakota (1)
Southern California (4437)
Tennessee (177)
Texas (1758)
United States (40411)
Utah (340)
Vermont (1)
Virginia (264)
Washington D.C. (81)
Washington State (926)
West Virginia (4)
Wisconsin (111)
Wyoming (2)
724,382 Results for "hill rom inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill
November 13, 2025
·
6 min read
Biosenta Announces Engagement of Oak Hill Financial Inc.
Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) announces that it has entered into an agreement with Oak Hill Financial Inc. (“Oak Hill”) to provide business
January 11, 2024
·
3 min read
Press Releases
Co-Diagnostics, Inc. to Exhibit at BioUtah’s 2025 Life Sciences Day on the Hill
January 31, 2025
·
2 min read
Policy
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. (“OHAM”), an Exempt Market Dealer to provide capital markets advice related to the Company’s capital markets strategy.
March 8, 2024
·
7 min read
Press Releases
Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy
New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations
October 29, 2025
·
4 min read
Press Releases
Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine
July 11, 2025
·
5 min read
Press Releases
Rose Hill Life Sciences Appoints Biopharma Veteran Jama Pitman as Strategic Advisor
May 5, 2025
·
2 min read
Press Releases
Route 92 Medical Appoints Medtech Industry Veterans Mitch Hill and Lucas Buchanan to its Board of Directors
June 18, 2025
·
3 min read
Business
Benson Hill Reports Solid Full-Year 2023 Financial Results, Strengthens Balance Sheet
Benson Hill, Inc. (NYSE:BHIL, the “Company” or “Benson Hill”), an ag-tech company unlocking the natural genetic diversity of plants, today announced operating and financial results for the year ended December 31, 2023.
March 14, 2024
·
25 min read
Business
Benson Hill Announces Date of Fourth Quarter and Full Year Earnings Release
Benson Hill, Inc. (NYSE: BHIL, the “Company” or “Benson Hill”), an ag tech company unlocking the natural genetic diversity of plants, announced today that it will release its financial results for the full year and fourth quarter ending Dec. 31, 2023, before the market opens on Thursday, March 14, 2024.
February 7, 2024
·
1 min read
1 of 72,439
Next
